Literature DB >> 12620605

Prevalence and description of chronic daily headache in the general population in France.

Michel Lantéri-Minet1, Jean-Paul Auray, Abdelkader El Hasnaoui, Jean-François Dartigues, Gérard Duru, Patrick Henry, Christian Lucas, André Pradalier, Guy Chazot, Anne-Françoise Gaudin.   

Abstract

The objective of this study was to describe the epidemiology, clinical presentation and consequences of chronic daily headache (CDH) in France. A representative nation-wide sample of the general population was identified using a stratified sampling method. Ten thousand five hundred and eight-five subjects were screened in face-to-face interviews, and data collected using a standard questionnaire. An overall point prevalence of CDH in the general population of 2.98% was observed. Two-thirds of these subjects presented migraine-like features. Severity, functional impact and healthcare consumption were higher than in subjects reporting episodic migraine in the same sample. Of the subjects, 28.2% reported the most severe migraine disability assessment scores (Grades 3 and 4), compared to 12% of episodic migraineurs. A qualité de vie et migraine score of 68.4 was observed, indicating severely attenuated quality of life. Only 6.6% of subjects were taking prophylactic treatment, whilst 88% were using non-specific acute headache treatments. The frequency of physician consultations and laboratory examinations was significantly higher than in individuals with episodic headache. CDH is thus a relatively prevalent condition in the general French population, associated with an important burden of suffering and with considerable expenditure in the health service. Management of this condition is generally inappropriate.

Entities:  

Mesh:

Year:  2003        PMID: 12620605     DOI: 10.1016/s0304-3959(02)00348-2

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  49 in total

1.  [Eye pain and headache from the perspective of an ophthalmologist].

Authors:  H Wilhelm
Journal:  Ophthalmologe       Date:  2011-12       Impact factor: 1.059

Review 2.  Chronic daily headaches in children.

Authors:  Andrew D Hershey; Marielle A Kabbouche; Scott W Powers
Journal:  Curr Pain Headache Rep       Date:  2006-10

Review 3.  Disability in chronic daily headache: state of the art and future directions.

Authors:  Domenico D'Amico; L Grazzi; S Usai; A Raggi; M Leonardi; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

Review 4.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

5.  Long-term effects of a sensitisation campaign on migraine: the Casilino study.

Authors:  B Petolicchio; L Di Clemente; M Altieri; E Vicenzini; G L Lenzi; Vittorio Di Piero
Journal:  J Headache Pain       Date:  2010-04       Impact factor: 7.277

6.  Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.

Authors:  André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 7.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

8.  Prevalence of migraine and tension-type headache among adults in Jordan.

Authors:  Karem H Alzoubi; Nizar Mhaidat; Sayer Al Azzam; Yousef Khader; Saad Salem; Hanin Issaifan; Rania Haddadin
Journal:  J Headache Pain       Date:  2009-04-23       Impact factor: 7.277

Review 9.  Estrogen and chronic daily headache.

Authors:  Dawn A Marcus
Journal:  Curr Pain Headache Rep       Date:  2004-02

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.